絞り込み

16641

広告

グレタさんCOPで演説 (デイリースポーツ)

【マドリード共同】地球温暖化対策の強化を求めるスウェーデンの少女グレタ・トゥンベリさん(16)が11日、気候変動枠組み条約第25回締約国会議(COP25)の会場...

  1. 小泉環境相「世界的な批判認識」 (デイリ...
  2. 吉野さん、一夜明け「持続可能社会への責務...
  3. 第36回保険者による健診・保健指導等に関...
  4. 「私たちは変われる」グレタさん COP2...

ニュース一覧

「"Turpie AGG"[Author]」の検索結果

35件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF.

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.

Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry.

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA.

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.

Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America.

Early Risks of Death, Stroke/Systemic Embolism and Major Bleeding in Patients with Newly Diagnosed Atrial Fibrillation: Results from the GARFIELD-AF Registry.

IMpact of Prolonged anticoagulation with Rivaroxaban On proVokEd Venous ThromboEmbolism recurrence: The IMPROVE-VTE Study.

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial fibrillation Patients with a Non-Sex-Related CHA2DS2-VASc Score of 1.

Global Prospective Safety Analysis of Rivaroxaban.

  1. 1
  2. 2
Sort by
※並べ替えは表示に時間がかかります